Arsenic trioxide prevents nitric oxide production in lipopolysaccharide ‐stimulated RAW 264.7 by inhibiting a TRIF‐dependent pathway

Arsenic trioxide (ATO) is one of the most potent drugs in cancer chemotherapy, and is highly effective in treating both newly diagnosed and relapse patients with acute promyelocytic leukemia (APL). Despite a number of reports regarding the molecular mechanisms by which ATO promotes anti‐tumor or pro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Takahashi, Miyuki, Ota, Akinobu, Karnan, Sivasundaram, Hossain, Ekhtear, Konishi, Yuko, Damdindorj, Lkhagvasuren, Konishi, Hiroyuki, Yokochi, Takashi, Nitta, Masakazu, Hosokawa, Yoshitaka
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2012
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657247/
https://ncbi.nlm.nih.gov/pubmed/23106696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12053
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak